Farhad Abtahian

Farhad Abtahian practices at Rochester General Hospital in Rochester, New York, part of Rochester Regional Health.

Farhad Abtahian's NPI, 1518166925, was assigned on July 16, 2007. Farhad Abtahian graduated from Perelman School of Medicine at the University of Pennsylvania in 2007. Farhad Abtahian holds New York license 279306-1.

Farhad Abtahian's primary practice is Rochester General Hospital, at 1425 Portland Avenue, Rochester, NY 14621 in Monroe County. The practice phone is (585) 922-4000.

Farhad Abtahian's primary practice is Rochester General Hospital in Rochester, New York, part of Rochester Regional Health. Farhad Abtahian is also affiliated with Unity Hospital. The medical group on file is Rochester General Hospital. Dmand AI also links Farhad Abtahian to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Farhad Abtahian practices, 4 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Farhad Abtahian's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dmand AI has Farhad Abtahian's licenses on file in 2 states: New York and Massachusetts.

CMS data shows 187 Medicare services from Farhad Abtahian across 7 procedure codes in 2024, for 141 Medicare patients. Medicare paid $23,661 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 141 Medicare patients who saw Farhad Abtahian in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Farhad Abtahian's median patient age at 76, with 40% women.

In 2024, Farhad Abtahian wrote 1,265 Medicare Part D claims for 207 patients. 81% of them were for generic drugs. CMS names the drug for 1,144 of them, across 24 drugs with 11 or more claims each, at $227,451 in total drug cost. In 2023, CMS named 842 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Farhad Abtahian for performance year 2024, reported through an alternative payment model (APM). Farhad Abtahian accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Farhad Abtahian as offering telehealth. CMS counts 25 procedures of coronary angioplasty and stenting by Farhad Abtahian, more than 58% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 30 papers to Farhad Abtahian, published from 2011 to 2024. 2013 was the busiest year, with 10. The most frequent topics are Tomography, Optical Coherence, Coronary Artery Disease and Coronary Vessels. Farhad Abtahian has published most often in Am J Cardiol. Farhad Abtahian's most frequent co-authors are Michael Ritt Jaff, DO, Abhiram Prasad, MD and Jeremiah Peter Depta, MD.

Dmand AI links Farhad Abtahian to 1 clinical trial. Conditions studied include Myocardial Infarction and Infarction.

CMS Open Payments shows 761 general payments to Farhad Abtahian from 36 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 67% of the total. Edwards Lifesciences Corporation paid the most, $18,168.

Farhad Abtahian graduated from Perelman School of Medicine at the University of Pennsylvania in 2007.